Study wrapper · #1123
Peripheral nerve complications from medications utilised for weight loss: a systematic review.
Editor's note
The evidence base here is case reports, so incidence cannot be estimated and confounding by rapid glycaemic correction is impossible to separate from the drug itself. What the pattern does suggest is a rate-of-change signal rather than a drug-specific one: the median loss was more than a fifth of body weight in roughly five months. The authors recommend adequate nutritional status and avoiding ultrarapid HbA1c and weight decline, which is a reasonable precaution while prospective data are absent.
Plain-language abstract
A systematic review searched PubMed, Embase, and CINAHL through June 2026 for reports of new or worsening peripheral nerve problems in people taking weight-loss medications. It found 19 studies covering 31 individual cases plus one cohort of 103 people, nearly all published since 2024. Median weight loss was 20.4 kg, or about 21.8% of starting body weight, at a median rate of 3.7 kg per month, with symptoms appearing around 150 days in. Semaglutide or tirzepatide were involved in 83% of cases, and two-thirds of patients had diabetes or pre-diabetes. Presentations included fibular neuropathy, lumbosacral radiculoplexus neuropathy, and distal symmetric polyneuropathy.